The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial

(2021) Vedang Murthy et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer

(2020) Robert T. Dess et al.   JAMA Oncology

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data

(2020) Claire L Vale et al.   LANCET

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

(2020) Christopher C Parker et al.   LANCET

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

(2020) Andrew Kneebone et al.   LANCET ONCOLOGY

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

(2020) Paul Sargos et al.   LANCET ONCOLOGY

Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients

(2020) Cem Onal et al.   RADIOTHERAPY AND ONCOLOGY

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

(2019) Jeremie Calais et al.   LANCET ONCOLOGY

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

(2019) Christian Carrie et al.   LANCET ONCOLOGY

Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer

(2018) Daniel E. Spratt   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial

(2018) Mack Roach et al.   LANCET ONCOLOGY

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

(2017) William U. Shipley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?

(2016) M. L. K. Chua et al.   CLINICAL CANCER RESEARCH

Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study

(2016) Thomas M. Pisansky et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy

(2016) Rahul D. Tendulkar et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

(2016) Christian Carrie et al.   LANCET ONCOLOGY

Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial

(2014) Thomas Wiegel et al.   EUROPEAN UROLOGY

Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers

(2013) W. R. Polkinghorn et al.   Cancer Discovery

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

(2012) Michel Bolla et al.   LANCET

Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer

(2009) Jeff M. Michalski et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

(2009) Ian M. Thompson et al.   JOURNAL OF UROLOGY

RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer

(2008) Colleen A.F. Lawton et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS